Clinical Management of Acute Lymphoblastic Leukemia 2022
DOI: 10.1007/978-3-030-85147-7_13
|View full text |Cite
|
Sign up to set email alerts
|

Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 171 publications
0
1
0
Order By: Relevance
“… 7 , 8 In addition, there is a rare set of atypical leukemia with different clinical features. 9 There are several treatment options for leukemia patients including radiation, 10 chemotherapy, 11 monoclonal antibodies, 12 and transplantation of hematopoietic stem cells. 13 Once the disease has occurred, several therapeutic procedures are determined based on the morphologic evaluation of blood cells and bone marrow specimens, analysis of cell-surface expression of cytoplasmic markers, identification of chromosomal abnormalities, or screening for molecular/cytogenetic markers.…”
Section: Introductionmentioning
confidence: 99%
“… 7 , 8 In addition, there is a rare set of atypical leukemia with different clinical features. 9 There are several treatment options for leukemia patients including radiation, 10 chemotherapy, 11 monoclonal antibodies, 12 and transplantation of hematopoietic stem cells. 13 Once the disease has occurred, several therapeutic procedures are determined based on the morphologic evaluation of blood cells and bone marrow specimens, analysis of cell-surface expression of cytoplasmic markers, identification of chromosomal abnormalities, or screening for molecular/cytogenetic markers.…”
Section: Introductionmentioning
confidence: 99%